Get the Stockscreener App
5.8175
9.68%
0.5475
Climb Bio Inc stock is traded at $5.8175, with a volume of 322.72K.
It is up +9.68% in the last 24 hours and up +39.95% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$5.27
Open:
$5.63
24h Volume:
322.72K
Relative Volume:
0.27
Market Cap:
$396.15M
Revenue:
-
Net Income/Loss:
$-50.75M
P/E Ratio:
-7.7484
EPS:
-0.7508
Net Cash Flow:
$-44.43M
1W Performance:
+6.25%
1M Performance:
+39.95%
6M Performance:
+254.60%
1Y Performance:
+263.52%
1-Day Range:
$5.56
$5.9889
1-Week Range:
$5.0558
$5.9889
52-Week Range:
$1.05
$5.9889
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
5.81 | 359.33M | 0 | -50.75M | -44.43M | -0.7508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.02 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
797.94 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
846.97 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.83 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.38 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
This Taiwan Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Piper Sandler initiates Climb Bio stock with Overweight rating, $23 target - Investing.com UK
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - MarketBeat
CLYM: Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress - TradingView
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Climb Bio to Present at Upcoming Investor Conferences - The Manila Times
Top High Flyer Healthcare Stocks Revealed - Intellectia AI
Cheap high flyer healthcare stockshigh momentum and low valuation (CLYM:NASDAQ) - Seeking Alpha
Activity Recap: Can Barings BDC Inc weather a recessionPortfolio Update Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Day Trade: Can Climb Bio Inc sustain its profitabilityPortfolio Performance Report & Accurate Trade Setup Notifications - baoquankhu1.vn
Tech Rally: Will Vishay Precision Group Inc announce a stock split2025 Big Picture & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Macro: Can Climb Bio Inc outperform in the next rallyLayoff News & Daily Chart Pattern Signals - baoquankhu1.vn
Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer - Business Wire
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
Ten new option listings and two option delistings on January 22nd - TipRanks
HubSpot, Inc. (HUBS) Stock Analysis: Can It Climb 86.84% To Meet Analysts' Targets? - directorstalkinterviews.com
Climb Bio, Inc. (NASDAQ:CLYM) Short Interest Update - MarketBeat
ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year end - Seeking Alpha
ImmunityBio shares climb 3% premarket after company's prelim quarterly revenue exceeds estimates - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
Resistance Check: How Climb Bio Inc stock benefits from tech adoption2025 Bull vs Bear & Long-Term Growth Portfolio Plans - Bộ Nội Vụ
Patterns Watch: How Climb Bio Inc stock benefits from tech adoption2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Bộ Nội Vụ
Winners Losers: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - Bộ Nội Vụ
Bull Bear: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 Chart Watch & High Conviction Buy Zone Picks - Bộ Nội Vụ
Laser Focus WorldClimb Bio to Present at Upcoming September 2025 Investor Conferences - FinancialContent
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Update Report: Why analysts upgrade Climb Bio Inc stockJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
Can Climb Bio Inc. stock deliver sustainable ROEMarket Trend Review & Weekly Top Gainers Trade List - ulpravda.ru
Climb Bio advances clinical trials with first patients dosed in key studies - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO) - The Globe and Mail
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch - TipRanks
Climb Bio initiated with a buy at Freedom Capital - MSN
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - Sahm
Is Climb Bio Inc. stock oversold or undervaluedProfit Target & Low Risk High Reward Ideas - Улправда
Analyst Downgrade: Can Climb Bio Inc. stock maintain growth trajectoryJuly 2025 Summary & Low Risk Growth Stock Ideas - Улправда
How Climb Bio Inc. stock reacts to oil pricesTreasury Yields & Free Weekly Watchlist of Top Performers - Улправда
Climb Bio outlines 2026 clinical milestones and cash runway - TipRanks
Climb Bio advances clinical trials with first patients dosed in key studies By Investing.com - Investing.com South Africa
Pasadena Star-News: Local News, Sports, Things to DoClimb Bio, Inc.Common Stock (Nasdaq:CLYM) Stock Quote - FinancialContent
Climb Bio reports inducement grant under Nasdaq listing rule - MSN
Climb Bio, Inc.Common Stock (NQ: CLYM - markets.financialcontent.com
Climb Bio (NASDAQ:CLYM) Director Purchases $24,888.50 in Stock - MarketBeat
Alumis reports positive phase 3 results for psoriasis drug By Investing.com - Investing.com Australia
Climb Bio (CLYM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Climb Bio Inc Stock Analysis and ForecastSector Performance Review & Explosive Capital Growth Plans - Early Times
Alumis issues breach notice to Climb Bio over $3 million milestone payment - Investing.com India
Setup Watch: Will SBUX stock benefit from commodity pricesPortfolio Value Summary & AI Driven Price Forecasts - moha.gov.vn
Climb Bio appoints Edgar D. Charles as Chief Medical Officer - MSN
Alumis IncCo & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb BioSEC Filing - TradingView — Track All Markets
Alumis issues breach notice to Climb Bio over $3 million milestone payment By Investing.com - Investing.com South Africa
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jan 05 '26 |
Buy |
3.50 |
7,111 |
24,888 |
3,403,429 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Dec 11 '25 |
Buy |
2.18 |
213,099 |
464,556 |
3,294,856 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Dec 12 '25 |
Buy |
2.86 |
101,462 |
290,181 |
3,396,318 |
| Brennan Aoife | President and CEO |
Jun 30 '25 |
Sale |
1.22 |
20,618 |
25,154 |
48,132 |
| Pimblett Emily | SVP, Finance & CAO |
Jun 20 '25 |
Sale |
1.24 |
1,242 |
1,540 |
18,888 |
| Pimblett Emily | SVP, Finance & CAO |
Mar 20 '25 |
Sale |
1.31 |
1,199 |
1,571 |
15,130 |
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):